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Basic Overactive Bladder definition and patho-
physiology
The common OAB definition was given in
2002 by the International Continence Society (ICS)
as urinary urgency with or without urge inconti-
nence, usually associated with frequency and noc-
turia, in the absence of proven pathological or meta-
bolic disorders (such as: lower urinary tract (LUT)
infection, bladder cancer, benign prostatic enlarge-
ment) or other obvious pathology (1). However, the
last reviewing in the ICS 2002 terminology report,
published in 2006, recommends replacement of cur-
rent terms in the definition given above. ìUrge
incontinenceî is suggested to be replaced with
ìurgency incontinenceî to underline that inconti-
nence is due to urgency and not urge (understood as
a ìdesireî). According to 2006 update, the word
ìfrequencyî should be substituted by the term
ìincreased day time frequencyî. Thus, the reviewed
OAB definition is urgency with or without urgency
incontinence (UI), usually with increased daytime
frequency and nocturia (2).
OAB is common clinical entity, with global
prevalence ranging 8ñ14% according to different
studied populations, depending on sex, age and dif-
ferences in accepted OAB definition. Generally,
OAB occurrence increases with age and is more
common in women than men. Selected reports
describing OAB prevalence in western countries
are given in Table 1 (3).
Urinary bladder plays a role in urine storage
and voiding. Its functioning is regulated by the
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peripheral and central nervous system. At least two
types of afferent neurons innervate the urinary blad-
der. One of them are mechanosensitive, myelinated
Aδ fibers, activated by both low, non-nociceptive
and high-nociceptive intravesical pressure. The
other ones are C-fibers which respond to many
chemical irritations. These fibers are suspected to be
mostly implicated in OAB pathogenesis. During fill-
ing (storage phase), an activation of afferent Aδ
fibers takes place due to bladder distention and
urothelial signals. The impulses pass the dorsal root
ganglion (DRG) and are conveyed via pelvic nerve
(some of them also via hypogastric one) to peri-
aqueductal grey nucleus (PAG) and then to
suprapontine regions, which temporally inhibits
voiding, deciding of voluntary control of micturi-
tion. PAG, in turn, communicates with the pontine
tegmentum. One can distinguish two different pon-
tine regions: dorsomedially located M region
(Barringtonís nucleus), which is said to be a pontine
micturition center (PMC) and more laterally located
L region, which is regarded to be pontine urine stor-
age center (PSC), responsible for suppressing blad-
der contractions. The efferent arm of the micturition
(emptying phase) reflex starts in PMC; the impulses
are conveyed to the sacral S2-S4 spinal parasympa-
thetic nucleus. This nucleus contains preganglionic
nerves which project to the bladder. Detrusor con-
tractions are initiated via acetylcholine (Ach) and
some non-adrenergic non-cholinergic (NANC) neu-
rotransmitters release from postganglionic fibers.
Bladder is also innervated with sympathetic nerves,
originating from the intermediolateral nuclei in the
thoracolumbar region (Th10-L2) of the spinal cord.
Sympathetic signals are conveyed via both pelvic
and hypogastric nerves. Physiologically, during
storage phase, no spinal parasympathetic activity
and bladder contractions occur and increased sym-
pathetic discharge contributes to bladder relaxation
with urethral smooth muscle and urethral and pelvic
floor striated muscles keeping the outflow closed.
On the other hand, during voiding, the decreased
sympathetic activity contributes to bladder outflow
opening which, in connection with increased
parasympathetic input, lead to bladder contractions
and emptying (4, 5). 
Concerning the physiological implicates, two
main pathophysiological theories have been pro-
posed ñ neural and myogenic ones. The first one
focuses on both central and peripheral innervation
disturbances. OAB may result from a lack of central
nervous inhibition of voiding (in cerebrovascular
diseases, multiple sclerosis, Parkinsonís disease,
spinal cord injuries). This clinical entity can also
occur as a result of sensitization of afferent nerves
together with abnormal urothelium activity. These
local mechanisms seem to be especially interesting
targets for future OAB pharmacological agents.
Factors which may be involved in neurogenic OAB
pathomechanism are: bradykinin, catecholamines,
substance P (SP), calcitonin-gene related peptide
(CGRP), vasoactive intestinal peptide (VIP),
tachykinins, enkephalins, vanilloids, prostanoids,
nerve growth factor (NGF) and many others. There
are also evidences that chronic inflammatory blad-
der is characterized by overexpression of nitric
oxide synthase and NO release form capsaicin-sen-
sitive afferents. NO is a molecule relaxating smooth
muscles around the bladder outlet and thus con-
tributing to urethral pressure drops that precede
involuntary bladder contraction. VIP seems to be an
inhibitory agent in efferent parasympathetic path-
ways and ñ together with SP ñ an excitatory factor
in bladder afferents. It was discovered that VIP con-
Table 1. Selected studies reporting overactive bladder prevalence in Western countries (3).
Study Age of Prevalence in Prevalence in Both genders
year respondents men population [%] women population [%] prevalence [%] Reference
2001 ≥ 40 15.6 17.4 16.6 (45)
2003 ≥ 18 16.0 16.9 16.5 (46)
2004 ≥ 35 14.8 21.2 18.1 (47)
2005 ≥ 40 17.4 25.6 21.5 (48)
2005 21ñ91 10.2 16.8 13.5 (49)
2006 ≥ 18 10.8 12.8 11.8 (50)
2007 18ñ79 6.5 9.3 8.0 (51)
2007 ≥ 18 13.1 14.7 13.9 (52)
2008 ≥ 18 NA 13.0 13.0 (53)
NA ñ not available
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centration in overactive bladder smooth muscles is
reduced when compared to normal bladder leading
to the conviction that loss of its inhibitory impact
may promote bladder overactivity. These findings
also hold promise for future therapies ameliorating
OAB. The role of calcium influx in unstable
myocytes is also emphasized. Apart from neuro-
transmitter disturbances mentioned above, poor cal-
cium and potassium ion regulation is proposed as
another potential mechanism leading to increased
cells depolarization and detrusor instability, thus
agents affecting calcium influx are also expected to
be introduced in the future OAB treatment. The
important role in bladder overactivity is attributed to
C-fibres, which may be overresponsible to many
chemical stimuli. Moreover, abnormal spontaneous
bladder activity called ìmicromotionsî may arise
from enhanced muscarinic receptors stimulation by
acetylocholine released in inadequate amount in
basal conditions (1, 4, 6, 7). 
OAB pathogenesis, according to myogenic
theory, may be also associated with bladder wall
rebuilt and reduced compliance and abnormal elec-
trical cells excitation. In the normal bladder, foci of
electrical activity spread across small number of
coupled neighboring cells. Thus, physiologically,
excitatory nerve input must be delivered to a large
number of smooth cells to trigger an organized blad-
der contraction. In OAB muscle, dysfunctional elec-
trical coupling between smooth muscle cells enables
small foci of electrical impulses to be propagated
beyond their normal range. As a consequence, it
may be concluded that normal bladder is character-
ized by scattered contractions which appear locally,
Table 2. Pharmacological agents used for OAB treatment, assessed by the International Consultation on Incontinence, Paris, 2001 (9, 10).




Antimuscarinic Trospium 1 A
Atropine 3 C
Hyoscyamine 3 C






Antidepressant Imipramine 3 C





Terazosin 3 C  
Clenbuterol 3 C
β-Adrenergic agonists Salbutamol 3 C
Terbutaline 3 C
Cyclooxygenase inhibitors Flurbiprofen 2 C
ñ prostaglandin synthesis 
inhibitors
Indomethacin 2 C
Level 1 ñ recommendation based on randomized controlled clinical trials.
Level 2 ñ recommendation based on good quality prospective studies. 
Level 3 ñ recommendation based on retrospective case-control studies. 
Level 4 ñ recommendation based on case series. Grade A ñ highly recommended ñ 
based on level 1 evidence. Grade B ñ recommended ñ based on level 2 or 3 ñ 
evidence. Grade C ñ recommended with reservation ñ based on level 4 evidence. 
Grade D ñ not recommended ñ based on evidence inconsistent/inconclusive.
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while in overactive bladder these local activities are
more prone to global spread. The electrical abnor-
malities may be due to altered bladder wall structure
(1, 2). 
Summarizing, bladder contractions are under
complex neural control and drugs targeting afferent
or efferent arms of micturition arc, reducing or block-
ing locally released various neurotransmitters or
directly affecting bladder smooth muscles are regard-
ed to be effective in bladder overactivity treatment. 
Non-pharmacological OAB management 
Treatment options of OAB involve both non-
pharmacological, such as behavioral and psycholog-
ical training and pharmacological interventions,
based on the OAB etiological theories mentioned
above. Other clinical OAB implications concern
neuromodulation and surgery, although the initial,
first-line therapy is a combination of lifestyle modi-
fication, pelvic floor muscle exercises, bladder train-
ing and antimuscarinic drugs administration.
The goal of OAB non-invasive treatment is to
increase urine volume triggering micturition, reduc-
tion of urinary frequency and nocturia, decrease
urgency and urgency incontinence episodes (3, 8). 
Lifestyle intervention should be introduced in
each OAB patient and involve fluid limitation,
avoiding both high water-containing foods (fruits
and vegetables) and fluid input in the evening hours
before going to bed, stopping smoking, caffeine
reduction and body mass decrease. The bladder
training results in bladder capacity increase and
voiding intervals extension with overactive bladder
contractions, urgency and urge episodes reduction
because of increased feedback inhibition. Bladder
exercise is usually accompanied by pelvic floor
muscle training (PFMT) in which patient is taught to
tight the pelvic floor when an involuntary contrac-
tions start. The same mechanism ñ contracting the
pelvic floor led to a detrusor decline and urethral
pressure increase occurs in electrical stimulation.
Additionally, some positive effects of hypnotherapy
and acupuncture were reported although they play
only marginal role and their effectiveness is not
long-term mantained (3, 8). 
Current OAB pharmacotherapy
In the past, agents used in OAB treatment
included ìoldî antimuscarinics (such as propanthe-
line, methantheline, emepronium, dicyclomine,
terodiline), spasmolytics (such as flavoxate), tri-
cyclic antidepressants (imipramine), prostaglandin
synthesis inhibitors (such as indomethacin, flur-
biprofen). However, these agents are not commonly
used because of lack of their efficacy and/or poor
tolerability. At present, several classes of drugs have
been approved in OAB treatment. They are present-
ed in Table 2 (9, 10). 
Only for a limited number of these agents
acceptable efficacy and safety were demonstrated in
randomized clinical trials. Thus, they have been
found to fulfill the criteria for level 1 evidence and
have been given A grade of recommendations by the
International Consultation on Incontinence. These
values were given parasympathycolytics (antimus-
carinic; anticholinergic) drugs, which are nowadays
the mainstream of OAB treatment (9, 10). 
The rationale for using of these agents comes
from physiological findings concerning voiding
reflex. As it was mentioned above, acetylcholine
released from efferent nerve endings stimulates
muscarinic receptors, located on detrusor smooth
muscles leading to contraction and micturition. It
seems thus simplest to block muscarinic receptors to
reduce detrusor abnormal contractility. Moreover, as
if OAB background is associated with enhanced
ìmicromotionsî, these agents exhibit particularly
valuable properties. The main problem associated
with antimuscarinics use is a lack of their absolute
selectivity. Ach is released not only in the bladder
but also in other organs, reacting on five (M1ñM5)
subtypes of muscarinic receptors. Therefore,
antimuscarinic usage in OAB treatment could have
side effects all over the body. In the detrusor,
urothelium, interstitial cells and nerve fibers, the
predominant muscarinic receptor is M2 one, but acti-
vation of M3 receptors (which account for one-third)
are responsible for direct bladder contraction. The
pharmacological studies suggested that M3 receptors
primarily mediate direct contractile response to Ach
and other agonists. Formerly it was thought that this
action was a result of intracellular calcium release
after phospholipase C activation and inositol phos-
phate synthesis. Nowadays it is regarded that human
bladder contraction depends on extracellular calci-
um entry through L-type calcium channels with sub-
sequent Rho kinases system activation. Interaction
of calcium ions with calmodulin activates myosin
light chain kinase resulting in contraction. The M2
receptors seem to mediate indirect contractile
response by abolition of relaxative effect, mediated
through stimulated β-adrenoreceptor. It was discov-
ered that β-agonists cause an increase of intracellu-
lar cAMP, which activates phospholipase A, dimin-
ishing calcium level and leading to smooth muscle
cell relaxation. On the contrary, M2 receptor activa-
tion leads to the adenylate cyclase inhibition and a
decrease of cAMP (5, 8). 
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Ach may be also released from nerve endings,
affecting the subtype unknown muscarinic receptors
located on urothelium, causing ATP release, which
in turn affects afferent activity via purinergic P2X3
receptors and other factors release which can modu-
late indirectly detrusor contractility. Thus, urotheli-
um and suburothelium that was traditionally viewed
only as a passive barrier separating intravesical
lumen from the internal bladder layers, nowadays is
regarded to participate in sensory bladder function-
ing by release of many neurotransmitters and vari-
ous receptors expression. Thus, urothelium and its
modulatory effects also seem to be interesting phar-
macological targets in novel OAB pharmacotherapy
(7). 
As it was mentioned, selectivity towards Ach
receptors is the one of the main problem associated
with antimuscarinic drugs use in OAB therapy.
These drugs may affect other than M2 and M3 recep-
tors or bind at more than one muscarinic receptors;
furthermore these drugs may block these receptors
outside of bladder. The restrictions decide of their
adverse effects (AE). Blockade of M3 receptor locat-
ed in the salivary glands, lower intestinal tract and
ciliary and iris smooth muscles in the eye are report-
ed to be most frequent AE, clinically expressed as
dry mouth, constipation and blurred vision.
Moreover, especially in the elderly population, cog-
nitive impairment during antimuscarinic therapy is
observed in some patients. All five muscarinic
receptor subtypes are present in central nervous sys-
tem. M1 one, located in hippocampus and cortex, is
attributed to play an important role in memory.
Thus, the affinity of antimuscarinics for the M1 sub-
type contributes to the probability of cognitive
impairment during therapy. Additionally, elderly
patients are more predisposed to such kind of side
effect because aging is associated with progressive
decrease in central cholinergic activity and with
reduction in the density of functioning muscarinic
receptors. Thus, muscarinic blockade achieved with
drugs together with physiologically observed dimin-
ished cholinergic activity result in increased like-
lihood of cognitive disturbances during therapy (5,
8, 11). 
The last essential AE, which is related to
antimuscarinic use is the risk of cardiac AE, partic-
ularly with the increased of heart rate through block-
ade of inhibitory input. Thus, cardiac tachycardia
and arrhythmia are one of the precautions given in
the individual antimuscarinic compound clinical
characterization. On he other hand, studies concern-
ing the essential tachycardia or other arrhythmias in
patients treated with tolterodine, trospium, solife-
nacin and darifenacin did not reveal serious arrhyth-
mia. Antimuscarinics are also suspected to induce
QT prolongation leading to the polymorphic ven-
tricular tachycardia (torsade de pointes), although
QT prolongation and its consequences are not relat-
ed to muscarinic receptor blockade but rather linked
to inhibition of some potassium channels. Results of
cardiac electrophysiological study of patients
receiving tolterodine showed no QT interval prolon-
gation. Similar results were obtained for trospium
and darifenacin. Summarizing, there is little evi-
dence that antimuscarinic drugs used in OAB treat-
ment increase the risk of cardiac AE, when adminis-
trated in recommended therapeutic doses (5, 8). 
The short pharmacokinetic and pharmacody-
namic description of currently used antimuscarinic
agents is given in Table 3 (5, 12ñ21).
Future approaches of OAB treatment
As it was described above, micturition process
involves complex peripheral and central mecha-
nisms, which seem to be potential places of novel
pharmacological agentsí action. Thus, it should be
expected that future OAB drugs will be focused on
various neurotransmission which organize micturi-
tion on different stages. 
Up to now, there is no drug affecting the void-
ing which acts centrally, although in both spinal and
supraspinal mechanisms there are many neurotrans-
mitters receptors which may be the target for central
drugs aimed at the micturition control. Glutamate,
glicyne, GABA, serotonin, noradrenaline,
dopamine, and enkephalines are examples of poten-
tial sites of therapeutic intervention. Moreover,
agents influencing these chemicals and other:
tachykinins, vanilloids, prostanoids released periph-
erally in bladder, as well as factors acting via differ-
ent neuronal and smooth muscle ion channels are of
special interest.
Glutamate and glycinergic systems
Glutamate is one of the most important excita-
tory neurotransmitters in central nervous system. It
has also been found in efferent arm of voiding
reflex, between the PMC and the preganglionic neu-
ron. Antagonists of NMDA (N-methyl-D-aspartic)
glutamate receptors were given in stroke-mediated
OAB rats and they diminished urodynamically
measured bladder overactivity. However, important
factor limiting the NMDA antagonists using are the
findings that glutamate is a key neurotransmitter in
brain, regulating most of its function. Thus, usage of
agents targeted in glutamate system must be associ-
ated with undesired influence of many other central
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mechanisms and so far are used only in experimen-
tal models. 
Contrary, an important inhibitory effect on the
spinobulbospinal and spinal micturition reflexes
may exert glycinergic neurons. Serum glycine level
was lower in patients with spinal cord injury, suffer-
ing from neurogenic OAB. Thus, similarly to gluta-
mate system, glycinergic one also seems to be cen-
tral target for novel OAB medicines development.
However, glycinergic neurons are also widely
involved in lot of spinal pathways, thus introduction
of glycinergic agents selectively affecting micturi-
tion to OAB therapy appears to be very laborious
and uncertain. 
It must be emphasized that taking the essential
role of both neurotransmitter systems in various cen-
tral functions into consideration, the development of
selective acting agents targeting only neuronal blad-
der controlling up to now is only hypothetical (4,
22). 
GABA-ergic system
The next central compound, identified as the
most important inhibitory neurotransmitter is
GABA. There are three GABA receptors, labeled as
GABAA, GABAB and GABAC. The predominant
brain receptors are GABAA and GABAB, while in
spinal cord GABAA receptors are more numerous.
It was discovered that GABA-type interneurons
play an important inhibitory role for both bladder and
especially central efferents. On the other hand,
GABAB receptor agonist ñ baclofen ñ administered
intrathecally in oxyhemoglobin induced detrusor
overactivity showed the inhibitory action, suggesting
that spinal GABAB agonists may be useful for con-
trolling micturition disturbances caused by C-fibers
activation in urothelium. There are also clinical evi-
dences demonstrating baclofen efficacy in patients
with neurogenic OAB, secondary to spinal lesions,
although the desired effects were accompanied by
high incidence of intolerable adverse effects, which
made patients to decline therapy. Summarizing,
blockade of GABAA and GABAB receptors lead to
micturition stimulation, thus activation of these
receptors may be co-responsible for inhibition of mic-
turition reflex. Similarly, inhibition of GABA-break-
down or GABA reuptake also produces an inhibitory
effect on micturition and agents acting via this mech-
anism may be considered as potentially useful in
future OAB pharmacotherapy (4, 22). 
Serotonin and serotonin receptors
The neurotransmitter, which is widespread in
central regions, where afferent and efferent impuls-
es from and to LUT are conveyed, is serotonin.
According to chemical structure, signaling pathways
and pharmacological effects, the serotonin receptors
are usually divided into seven classes (5HT1ñ5HT7)
with some subtypes. All of these receptors are G-
protein coupled, except 5HT3 ones which are ligand-
gated ion channels. 
Depending on receptor type and its localiza-
tion, serotonin may exhibit either inhibitory or exci-
tatory effects on micturition. However, the existence
of the descending, inhibitory pathway with sero-
tonin as a key neurotransmitter is unchallenged. De
Groat gave the model explaining the serotonin role
in the LUT. According to it, raphe nucleus neurons
release serotonin at several lumbosacral levels. The
fundamental role in LUT serotoninergic system play
inhibitory 5HT1A receptors, located on preganglion-
ic parasympathetic neurons, neurons conveyed
afferent impulses to the brain and on interneurons
providing an inhibitory impact on motoneurons pro-
jecting the striated urethral sphincter. The neurons
of raphe nucleus also express inhibitory 5HT1A
autoreceptors. Thus, blockade of these receptors
would bring increased serotonin release and aug-
mentation of spinal inhibitory system towards the
bladder. It is in accordance with the experimental
observations that electrical stimulation of raphe
nucleus causes inhibition of bladder contractions.
The main disadvantage of the proposed theory are
the unexpected and sometimes opposite effects aris-
ing from serotonin and its agonists influence on
other serotonin receptors. For example, experimen-
tal intrathecal serotonin administration increased
micturition volume but blockade of spinal 5HT2 and
5HT3 decreased bladder capacity (4, 22, 23). 
Apart from limitations underlying complicated
and still undiscovered pharmacological networks
and effects between various serotonin receptors,
blockade of central 5HT1A receptors represents a
possible target for micturition control in OAB. 
In the light of serotonin important role in void-
ing process, there is a question how drugs interfer-
ing with serotonin reuptake, are affecting the blad-
der functioning. The serotonin deficiency is
observed in depression and probably in OAB.
Studies are needed to explore if the antidepressants
focused on serotonin mechanisms are effective in
micturition control in depressed patients only or in
all OAB patients. This problem has not been
absolutely explored so far. Moreover, some studies
are contradictory ñ there are evidences that some
selective serotonin reuptake inhibitors (SSRI), such
as citalopram, did not alter bladder contraction.
Combined noradrenaline and serotonin reuptake
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inhibitors (SNRI) ñ e.g., venlafaxine, increased
bladder capacity. On the other hand, imipramine
(Tricyclic Antidepressive Drug ñ TAD) depressed
rat bladder activity. Thus, pharmacotherapy with
SSRI, SNRI or TAD may affect voiding process.
Among all agents acting via monoamine reuptake
inhibition, duloxetine is the most studied compound.
This drug was demonstrated in animal model to
increase neural activity to the striated urethral
sphincter and to increase bladder capacity through
its effect on the central mechanisms. Beneficial
effect of duloxetine was revealed in clinical study in
female patients with OAB (ìwet OABî) and without
(ìdry OABî) urinary incontinence. Thus, the con-
cept is enforced that duloxetine may have the poten-
tial for OAB treatment (4, 22, 23). 
Dopamine and dopamine receptors
Similarly as in the case of serotonin pathways,
central dopamine paths exist, exerting both inhibito-
ry and stimulatory effects on bladder function.
Experimental studies revealed that activation of D1
receptors represses micturition while D2 ones acti-
vates micturition. Consistently, D1 receptors block-
ade stimulates but D2 ones inhibits or has little effect
on the bladder. Thus, D1 receptors are regarded to
tonically inhibit the voiding reflex while D2 recep-
tors contribute to the voiding reflex. The indirect
evidence that dopamine and dopamine receptors
take part in voiding physiology and pathophysiolo-
gy are findings that patients with Parkinsonís dis-
ease often suffer from OAB symptoms. Since the
pathogenesis of Parkinsonís disease is associated
with destruction of striatal, dopaminergic neurons, it
may be concluded that loss of D1 receptors is
responsible for OAB development in Parkinsonís
disease patients. 
The clinical therapeutic opportunities focused
on dopamine system involve highly selective D1
receptor agonists development; although this area is
still poorly explored and further studies are required.
Especially that levodopa ñ the most clinically used
in the Parkinsonís disease treatment dopamine pre-
cursor, has been described to worsen OAB symp-
toms, probably due to its unselectively influence of
all dopaminergic receptors. Similar observations
were done in experimental administration of apo-
morphine or bromocriptine (4, 22). 
Noradrenaline and noradrenergic receptors
Noradrenaline neurons originating from the
locus coeruleus also seem to be co-responsible for
supraspinal control of micturition. Especially α1
receptors seem to be engaged in the sympathetic
neural control of LUT, although only their selected
subtypes modulate of reflex bladder activity. The
idea of application agents acting via α adrenorecep-
tors arises from the clinical observations, that α1-
adrenoreceptors antagonists used in the treatment of
benign prostatic hyperplasia (BPH), inhibit smooth
muscle contractions and reverse not only the
obstructive symptoms associated with bladder emp-
tying but also relieve the irritative BPH symptoms
(frequency, nocturia, urgency). It is regarded that
blockade of α1A subtypes ameliorate prostate hyper-
plasia and smooth muscle contraction while α1D ones
mediate the bladder irritative symptoms. It is con-
sistent with the findings that tamsulosin, a blocker
of both α1A and α1D receptors reduces overactive
bladder symptoms in men. The postulated mecha-
nism of α1 antagonists in bladder function improve-
ment is unclear, however, α1 receptors are expressed
on bladder sensory neurons and their activation may
contribute to enhancement of signaling of irritative
and nociceptive responses. Tamsulosin was also
proved to have an inhibitory effect on C-fibers ure-
thral afferents via TRPV1 receptors (24). 
β-Adrenoreceptors are also found in the blad-
der with the predominant β3 subtype (they account
up to 95% of all β-receptors). In experimental stud-
ies relaxation of bladder body after terbutaline,
salbutamol and clenbuterol was demonstrated, thus
β3-receptor selective agonists have been studied for
years as a potential OAB modern drugs. These kinds
of drugs would produce fewer if any cardiovascular
adverse effects than β1- or β2-agonists, thus they
would be safe agents. The detrusor relaxation after
β-agonists is mediated mostly via increasing intra-
cellular cAMP level although the activation of large-
conductance Ca-activated K (BK) channels seems to
be also possible. The other therapeutical option
resulting in the same effect (an increase of cAMP) is
phosphodiesterase (PDE), an enzyme degrading
cAMP blocking. There are six isoforms of PDE,
found in bladder smooth muscles: PDE1-5 and
PDE9. PDE1 inhibitor ñ vinpocetine, PDE4
inhibitor ñ rolipram and PDE5 one ñ vardenafil
exhibited in clinical trials efficacy in ameliorating
irritative LUT symptoms. Further studies are
required to establish the optimal doses, precise indi-
cations and patient population. As it was mentioned,
the main target of β3-agonists is detrusor smooth
muscles, although lately it has been suggested that
urothelial β3-receptors are also presumed pharmaco-
logical goals. Stimulation of these receptors results
in urothelial nitric oxide (NO) release, which modu-
lates afferent nerves activity. Moreover, hypotheti-
cal urothelial derived inhibitory factor, which is not
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identified with NO is released, that inhibits smooth
muscles contractions (4, 22, 24). 
Nonadrenergic-noncholinergic system: enkephal-
ins, purinergic system, endothelins, tachykinins,
nociceptin
Enkephalins ñ endogenous opioid peptides are
widely distributed in the brain, including areas
involved in micturition (PAG, PMC, spinal
parasympathetic nucleus). Usually, three opioid
receptors are distinguished: µ, δ and κ, which bind
morphine and other opioids, mediating the inhibito-
ry effects on micturition. It was experimentally and
clinically demonstrated that morphine increased
bladder capacity and blocked bladder contractions
when administrated intravenously, intraperitoneally
or intrathecally. Moreover, naloxone ñ an µ opioid
antagonist abolished the effects mentioned above.
These findings suggest that µ receptors may perform
an inhibitory control of the micturition and it brings
another therapeutic approach. However, µ-receptor
agonists are not expected to be introduced in OAB
therapy due to their adverse effects, such as nausea,
respiratory depression, constipation, pupillary con-
traction and others. Among opioid agents, tramadol
ñ with combinatory effect on opioid receptors with
inhibition of serotonin and noradrenaline reuptake
seems to be attractive because of its fewer adverse
effects. It seems possible that tramadol may be used
in treatment of OAB. Similarly, after administration
of partial µ-receptor agonist and κ-antagonist ñ
buprenorphine, an improvement in micturition man-
ifested as increased bladder capacity and decreased
micturition pressure were observed. Thus, the most
probably is that apart from µ receptors, stimulation
of other ones is engaged in micturition (4, 22).
The next important transmission in NANC
system is purinergic one, with ATP as a main mole-
cule. There are several receptors for ATP:
metabotropic P2Y and ionotropic P2X1ñ7 families.
Detrusor muscle cells possess P2X1, P2X2, P2X4
subtypes, bladder nerves are supplied with P2X1,
P2X2, P2X3 and P2X5 ones while urothelial cells
express P2X2, P2X3 and P2X5 receptors. Purinergic
transmission is regarded to affect both afferent and
efferent endings. ATP is a molecule being co-respon-
sible for afferent sensitization and neurogenic inflam-
mation development. Moreover, there are evidences
suggesting ATP role in the bladder contraction via
P2X1 and that ATP is released from urothelial cells
playing an autocrine and paracrine role. Experimental
studies suggest that P2X channels blockers offer the
next novel therapeutical option, although these stud-
ies are still early and need to be advanced (22).
Another chemicals involved in bladder con-
trolling are endothelins (ET1ñ3), showing affinity to
ETA and ETB receptors. Endothelins are attributed to
have a regulatory role of detrusor tone and a modu-
latory impact on detrusor neurotransmission.
Moreover, ET also exerts strong mitogenic effect on
smooth muscle cells, thus antagonization of ET
activity is expected to prevent detrusor hypertrophy
and would be of special interest in obstructive and
diabetic OAB patients. It is consistent with the
experimental findings revealing higher ET receptors
density amount in obstruction-induced OAB. The
predominant endothelin type is ET1, which mediat-
ed via ETA receptor slowly developing bladder con-
traction. Thus, selective ETA receptor blockade
could be an effective treatment for OAB. The next
therapeutic approach seems to be endothelin con-
verting enzyme inhibitors ñ during endothelin syn-
thesis an enzymatic cleavage of proendothelin
occurs, similarly to angiotensin II synthesis from its
precursor angiotensin I with angiotensin converting
enzyme. Endothelin converting enzymes inhibitors
are also considered to be promising novel OAB drug
candidates (22). 
An important physiological and pathophysio-
logical role in central and peripheral bladder func-
tion controlling plays a tachykinin system.
Tachykinin family involves several peptides, includ-
ing substance P (SP), calcitonin gene-related peptide
(CGRP) and neurokinins A (NKA) and B (NKB),
which possess the affinity for NK1, NK2 and NK3
receptors, respectively. These receptors were
demonstrated in various brain regions, including
those ones which take part in micturition.
Tachykinins acting via central and peripheral mech-
anisms facilitate the micturition. When administrat-
ed SP-saporin conjugate (SP-SAP ñ a conjugate of
substance P (SP) to saporin, a ribosome inactivating
protein from Saponaria officinalis), an improvement
in overactivity symptoms was observed. SP-SAP
has been shown effective in destroying neurons
expressing the neurokinin-1 receptor (NK1R) in the
striatum and lamina I of the dorsal horn of the spinal
cord. Tachykinins released peripherally from
urothelial cells and capsaicin-sensitive afferents
contribute to local and spinal micturition reflexes.
Increased tachykinins release is suspected to be
involved in OAB pathogenesis, and NK2 antagonists
were effective to reduce experimental detrusor
hyperactivity in the rat. Moreover, these compounds
influence vascular tone and permeability being co-
responsible for neurogenic inflammation develop-
ment. Tachykinins and their pathophysiological role
in OAB are widely studied in experimental models
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nowadays. There is also randomized, controlled
clinical trial of women with urge urinary inconti-
nence, showing that aprepitant ñ NK1 antagonist
were effective in ameliorating their OAB symptoms.
These all findings support the idea that counteract-
ing effects of tachykinins may be an interesting
pharmacological tool in future OAB treatment (22,
23, 25). 
There is also another molecule arousing the
interest in searches novel OAB treatment options.
Nociceptin ñ orphanin FQ (N/OFQ) was discovered
to be endogenous agonist of opioid-like receptor-4
(NOP receptor). Nociceptin inhibits micturition by
blockade of afferent C-fibers discharge in rats. In
experimental studies this compound was also
demonstrated to have central inhibitory effect,
affecting supraspinal micturition centers. There are
also preliminary clinical studies confirming the
nociceptin efficacy (although the studied OAB pop-
ulation was relatively small and the large clinical tri-
als are needed). Several selective NOP receptor ago-
nists were also synthesized making this receptor a
realistic new target for OAB drug design (22, 26). 
Vanilloid receptors and primary afferent nerves
As it was mentioned above, there are two main
afferent pathways carrying the impulses from the
bladder to central nervous system. The major path-
way is composed of myelinated Aδ fibers but in
addition to this dominant route there are also
unmyelinated C-fibers, conveying afferent impulses
mostly in response to chemical irritants (e.g.,
inflammation mediators). These fibers are said to be
capsaicin-sensitive afferents ñ it means that after ini-
tial stimulation with capsaicin, subsequent long term
desensitization occurs. 
C-afferent fibers are located in the detrusor,
perivascularly and in the intramural bladder plexus
extending to urothelium and contain tachykinins,
which may be released from their endings, con-
tributing to neurogenic inflammation. Under physi-
ological conditions, these neurons transmit nocicep-
tive and thermoceptive information to the central
nervous system and regulate homeostatic reflexes,
such as bladder microcirculation. These afferents
are also involved in OAB pathophysiology, convey
pain sensation and provoke neurogenic inflamma-
tion, which destabilizes resting bladder activity and
affects complex interactions between all bladder
structures (afferent/efferent innervation, detrusor
smooth muscles, urothelium and others) (7, 22, 23).
Capsaicin, stimulatory agent for C-fibers is a neuro-
toxin, belonging to the group of vanilloids, together
with resiniferatoxin and their analogues because
these compounds share a common structural element
ñ a homovanillyl group. Thus, capsaicin-sensitive
neurons are also called vanilloid-sensitive ones to
underline that these fibers are either activated or
inactivated by vanilloids in a receptor-mediated way. 
Capsaicin is the active ingredient of the hot
chili pepper (Capsicum annuum), isolated for the
first time in 1846 and completely synthesized in
1930. Resiniferatoxin was obtained from the cactus-
like Euphorbia resinfera in 1975 and in 1989 it was
recognized as more potent analogue of capsaicin.
Both capsaicin and resiniferatoxin affect the vanil-
loid receptors located on afferent neurons, thus
being exogenous ligands. These receptors are
presently known as transient receptor potential
vanilloid subfamily 1 ñ TRPV1 and some endoge-
nous agonists were also found: protons, N-arachi-
donoyl-ethanolamine (anandamide), N-arachi-
donoyl-dopamine, N-oleoyl-dopamine, eicosanoid
acids and lipooxygenase products (22, 23, 27, 28). 
TRPV1, formerly known as vanilloid receptor
type 1 is a non-specific ion channel, stimulated by
heat (> 43OC), low pH and exogenous (vanilloids)
and endogenous agonists mentioned above. This
receptor represents TRP family of ion channels, also
called ìthermo-TRPî class. Usually, four heat-sensi-
tive channels, including TRPV1ñ4 and two ìcold-
sensitiveî TRMP8 (currently identified with cold
menthol receptor CMR1) and TRPA1 have been dis-
tinguished. Moreover, the TRP family was broaden
of two thermal-nonsensitive channels TRPV5 and
TRPV6. It must be emphasized that sensitivity to
vanilloids has been demonstrated for TRPV1 sub-
type so far and the influence of vanilloid compounds
on other TRPV subgroups remains still controversial
and requires further studies. It seems that TRPV1
channels play essential role in OAB, resulting from
pathological excitation C-afferents. The frequency
of bladder contractions in chronically inflamed rat
urinary bladder (cyclophosphamide inflamed rat
bladder) is increased and capsaicin administration
reduces the bladder motility in this OAB experi-
mental model. Under physiological conditions, the
TRPV1 role in regulation of normal bladder activity
is regarded to be of less meaning (29, 30). 
Chemical denervation of C-vanilloid afferents
after intravesical administration of capsaicin binding
TRPV1 was showed to be effective in overactive
bladder disturbances treatment. Most clinical studies
suggest that after this procedure, in 60% OAB
patients urodynamic improvement was achieved 1ñ2
months after capsaicin instillation with long-lasting
effect, even up to one year in some patients. This
compound is difficult to dissolve therefore ethanol-
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saline solutions must be used (mostly 30% ethanol).
Acute pain after capsaicin administration on bladder
mucosa and its irritation limit common clinical use of
the agent (although burning sensation was also noted
when administered was 30% ethanol with no cap-
saicin). Apart from this phenomenon, most of
patients reported initial worsening of OAB symp-
toms during first few days up to even two weeks after
capsaicin solution instillation. These adverse effects
are more seldom observed after resiniferatoxin,
which is estimated to be a thousand times more
selective and potent than capsaicin ñ this compound
is active at concentrations 100ñ10000 times lower
than capsaicin. It enables thus dose lowering and
showing fewer adverse effects. It is commonly
believed that resiniferatoxin favors desensitization of
C-fibers while capsaicin causes an initial excitation,
which then turns to C-fibers silence. It is unknown if
there are different mechanisms by these compounds
produce their effects, however, in both cases strong
role of single TRPV1 is emphasized. The possible
explanations are that resiniferatoxin has a higher
molecular weight than capsaicin and is more
lipophilic, thus has slower tissue penetration after
administration on mucosa. Secondly, it seems that
capsaicin after binding TRPV1 stimulates rapid in
onset but brief in duration inward ion current.
Contrary, resiniferatoxin induces slowly rising but
more sustained currents. These findings make
resiniferatoxin an interesting alternative to capsaicin
in therapeutic OAB efforts. What is surprising from
the clinical point of view, resiniferatoxin adminis-
tered intravesically had variable efficacy ñ it
increased cystometric bladder capacity (in part of
OAB patients of 31ñ136% and it was even reported
of 500%!!!), with no warm or burning sensation, but
this compound produced effects lasting only from 4
to several weeks, in dependence on the used
resiniferatoxin concentrations (22, 23, 28).
Summarizing, vanilloids are effective agents
in suppressing detrusor hyperreflexia, affecting the
afferent innervation of the bladder. However, the
precise role of C-fibers and their interactions
between bladder urothelium in normal and patho-
physiological conditions must be still evaluated. 
Prostanoids 
Prostanoids are heterogeneous group of mole-
cules derived from arachidonic acid in enzymatic
process of cyclooxygenation. This group includes
prostaglandins (PG) and thromboxanes (TX), syn-
thesized by cyclooxygenase (COX). It is known,
that there are at least two COX izoforms: COX-1,
responsible for the normal, physiological
prostanoids biosynthesis and COX-2, activated in
response to various pathophysiological stimuli,
especially mediators of inflammation. 
There are several prostanoid receptors: DP,
EP1ñEP4, FP, IP and TP, which bind preferentially
PGD2, PGE2 and TXA2. Prostanoids are synthesized
locally both in the detrusor and mucosa. PGE1, PGE2 and
PGF2α cause sluggish detrusor contraction. Moreover,
these compounds are regarded to elicit bladder afferent
activity, contributing to hypersensitization (31). 
Nonsteroidal antiinflammatory drugs
(NSAID) are COX inhibitors, which were found to
improve OAB symptoms (increase bladder capacity
and prolonged micturition intervals). The common
NSAID adverse effects (nephrotoxicity, antiplatelet
and ulcerogenic properties) limit their clinical use-
fulness. Thus, an increasing interest in prostanoid
receptors antagonists development is observed. It
was demonstrated in experimental model of rat
obstructive-derived OAB that one of the EP1 recep-
tor antagonists showed beneficial effects, thus these
kind of agents may also have potential as a treatment
of OAB in humans (22, 32). 
Ion channels ñ calcium channels
There are also efforts of introducing to OAB
pharmacotherapy agents directly affecting smooth
muscle contractility through the influence on
smooth muscles electrical properties. The action
potentials have different phases due to the coordi-
nated action of several ionic conductances. The
depolarization spike is a result of extracellular calci-
um entrance through the voltage-dependent L-type
calcium channels (VDCaC) with subsequent calci-
um release from sarcoplasmic reticulum through
ryanodine-sensitive calcium channels (RyRs). The
participation of T-type Ca channels is also consid-
ered, as calcium influx through these channels may
account for prolonged depolarization. The repolar-
ization phase results from the activation of both
voltage-dependent potassium channels KV and
large-conductance, calcium activated potassium
channels (BKCa). Then hyperpolarization occurs,
mediated through the small-conductance, calcium-
activated potassium channels (SKCa) and likely KV
channels, restoring the potential to the initial value.
There are also ATP-dependent potassium channels
which are suspected to be involved in detrusor
hyperpolarization and its relaxation (22). 
The studies targeting the agents affecting
detrusor smooth muscles action potentials focused
on the VDCaC antagonists, thus agents preventing
the depolarization phase. Nifedipine was shown to
have strong inhibitory effect on isolated bladder
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smooth muscles, but clinical studies investigating
the VDCaC antagonists are scarce, especially due to
their cardiovascular adverse effects. Thus, the local
use of the potent Ca-antagonists might be an inter-
esting therapeutic approach. Moreover, taking into
consideration the T-type calcium channels role in
depolarization, it seems that pharmacological
manipulation of T-type Ca channels would be anoth-
er future target in OAB treatment (33ñ35).
Ion channels ñ potassium channels
Potassium channels can be distinguished into
some subtypes, including: K ATP channels, KV
channels and large (BKCa), intermediate (IKCa)
and small (SKCa) conductance calcium-activated
channels, all expressed on bladder smooth muscles.
The key role seems to play BKCa channels, being
responsible for repolarization phase and opposing
both cholinergic and purinergic excitability of detru-
sor. The confirmation of the role BKCa channels in
OAB pathogenesis gave experimental studies with
mice with deletion of gene encoding a subunit of
BKCa channel. In this animal model, a rapid urody-
namic OAB features were developed. Thus, a calci-
um activated potassium channel opening drugs ñ
ìPotassium Channels Openers, KCOî, might have
the potential for treating OAB patients. One of them,
labeled as NS-8, undergoes preclinical studies
demonstrating suppression of micturition in rats.
Apamin, a selective SKCa blocker, was shown to
enhance bladder phasic contractions in animals.
Thus, these channels and agents opening SKCa can
be next interesting targets for drugs aiming to con-
trol micturition (22, 36, 37). 
K ATP channels are composed of K channel
pore and ATP regulatory subunit. This subunit may
be a place of another KCO group action that pro-
motes channel activity by antagonizing ATP-
induced ion exchange inhibition. There are evi-
dences that administration of ìoldî KCO targeting
ATP subunit ñ cromakalim, pinacidil and nicorandil
lead to detrusor relaxation in human. The similar
effects were demonstrated when these agents were
given to rats with obstructive OAB or in rats with
spinal cord injury. Several studies are ongoing being
aimed at finding more selective ìnewî KCO affect-
ing ATP regulatory subunit (22, 38). 
KV channels play an important role in the reg-
ulation of basic electrical activity of the detrusor.
There are evidences that agents opening these chan-
nels may be promising targets of future OAB treat-
ment. Retigabine is an antiepileptic drug that opens
KV channels. After i.v. and intracerebroventricular
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micturition volume and voiding intervals were
observed. The major disadvantage of KV openers is
their widespread and not predictable effects with
markedly pronounced blood pressure reduction, aris-
ing from KV openers nonselectivity. The cardiovas-
cular restrictions made rationale to study the effects
of KV openers administrated locally and there are
animal studies focused on the effects of agents
affecting KV channels, however, so far no KV open-
er has passed to further stage of studies (22, 39). 
Ion channels ñ sodium epithelial channels
The sodium epithelial channels ñ (ENaC, also
called ìdegenerin/epithelial sodium channelsî ñ
Deg/ENaC) family was discovered in early 1990s.
The summary name of this group of receptors is
derived from protein ìdegenerinî identified in
Caenorhadbitis elegans in which mutation of deg1
gene resulted in sensory neurons, involved in touch
perception degeneration. These channels are
blocked by amiloride and activated by mechanical
stimuli, low temperature, pH drop and still unidenti-
fied chemical ligands (30, 40). ENaC were found in
kidneys, distal colon, secretory glands and respirato-
ry airways, playing a key role in epithelial sodium
absorption. 
Recently, ENaC have been also found in lower
urinary tract (LUT) epithelia (renal pelvis, ureter,
urinary bladder) and in suburothelial afferent nerves
(30, 41). The subgroup of epithelial sodium chan-
nels, which are proton-gated and especially often
found in the urothelium and detrusor muscles, is
acid sensing ion channels (ASIC). The precise phys-
iological role of these channels remains unknown;
however, their disruption changes due to mechanical
influences. It seems that ENaC and ASIC have the
ability to change its sodium influx in dependence on
hydrostatic pressure ñ an increase in intrabladder
pressure may initiate activation of these channels
and trigger afferent endings. Thus, this mechanism
is of special interest in obstructive OAB model. It is
consistent with the observations that in human blad-
der the expression of ENaC is low but it markedly
rises in patients with obstructive bladders and OAB
symptoms. Thus, agents blocking ENaC/ASIC
might be considered as next hypothetical target for
future agents effective in OAB treatment. However,
the studies on ENaC/ASIC LUT selectively agents
are still elementary and poorly developed (30, 42). 
Botulinum toxin (Botox) 
Botulinum toxin (BTX), derived from
Clostridium botulinum acts by decreasing acetyl-
choline release from presynaptic endings of cholin-
ergic nerves and provides long-lasting neuronal
blockade. BTX is expected to cleavage SNARE
(Soluble NSF Attachment Protein Receptors) pro-
tein SNAP-25, responsible for the exocytosis of
neurotransmitters. There are seven subtypes of BTX
and mostly used is BTX-A. Taking into considera-
tion the cholinergic mechanism of efferent bladder
supplying, the ability of BTX-A to prevent acetyl-
choline release with subsequent decreased bladder
contractility made this compound an interesting
approach to OAB future treatment. The produced
chemical denervation is reversible as axons regener-
ate in 3ñ6 months. Botox does not cross the blood-
brain barrier thus has no central effects. Moreover, it
has recently been postulated that BTX-A also affects
afferent neurotransmission (22). The mechanism of
BTX-A action seems to be not only associated with
efferent endings blocking but also with inhibition of
release of tachykinins from afferents together with
downregulation of purinergic (P2X3) and TRPV1
receptors expression (27). 
There are several clinical reports showing
BTX-A efficacy in improvement of OAB symptoms
and decrease of involuntary detrusor contractions.
Repetitive injections of BTX-A resulted in persist-
ent significant therapeutic effect although optimal
doses, precise route of administration and fully elu-
cidating the BTX-A mechanism of action remain for
further studies. Despite the incomplete knowledge,
BTX-A promises to become one of the major future
treatment for OAB (43, 44). 
CONCLUSIONS
Current options for pharmacotherapy of over-
active bladder are unfortunately scanty and insuffi-
cient. Increasing understanding OAB pathophysiol-
ogy enables development of new agents, selectively
targeting the OAB pathomechanisms, both central
and peripheral. Thus, it should be expected that in
close future the OAB pharmacotherapy will be more
effective and safer. The aim of this article was to
give rationale for searching other therapeutical
approaches. The main directions in novel OAB
pharmacotherapy are summarized in Table 4.
REFERENCES
1. Chu F.M., Dmochowski R.: Am. J. Med. 119,
3S (2006).
2. Hashim H., Abrams P.: Curr. Opin. Urol. 17,
231 (2007).
3. Cartwright R., Renganathan A., Cardozo L.:
Curr. Opin. Obstet. Gynecol. 20, 489 (2008).
Current management and future perspectives of overactive bladder (OAB) pharmacotherapy 821
4. Andersson K.E., Pehrson R.: Drugs 63, 2595
(2003).
5. Abrams P., Andersson K.E.: BJU Int. 100, 987
(2007).
6. Griffiths D.J.: Curr. Urol. Rep. 5, 348 (2004).
7. Moore C.K., Goldman H.B.: Curr. Urol. Rep. 7,
447 (2006).
8. Hashim H., Abrams P.: Drugs 64, 1643 (2004).
9. Andersson K.E., Chapple C., Wein A.: World J.
Urol. 19, 294 (2001).
10. Wein A., Rackley R.R.: J. Urol. 175, S5 (2006).
11. Epstein B.J., Gums J.G., Molina E.: Am. Fam.
Physician 74, 2061 (2006).
12. Hegde S.S.: Br. J. Pharmacol. 147, S80 (2006).
13. Andersson K.E., Chapple C.R.: World J. Urol.
19, 319 (2001).
14. Madersbacher H., Murtz G.: World J. Urol. 19,
324 (2001).
15. Doroshyenko O., Fuhr U.: Clin. Pharmacokinet.
48, 281 (2009).
16. Skerjanec A.: Clin. Pharmacokinet. 45, 325
(2006).
17. Wefer J., Truss M.C., Jonas U.: World J. Urol.
19, 312 (2001).
18. McKeage K., Keating G.M.: Drugs 69, 731
(2009).
19. Rovner E.S.: Drugs 64, 2433 (2004).
20. Doroshyenko O., Jetter A., Odenthal K.P., Fuhr
U.: Clin. Pharmacokinet. 44, 701 (2005).
21. Guay D.R.P.: Clin. Pharmacokinet. 42, 1243
(2003).
22. Sacco E., Pinto F., Bassi P.: Int. Urogynecol. J.
19, 583 (2008).
23. Cannon T.W., Chancellor M.B.: Clin. Obstet.
Gynecol. 45, 205 (2002).
24. Michel M.C., Vrydag W.: Br. J. Pharmacol.
147, S88 (2006).
25. Wiley R.G., Lappi D.A.: Neurosci. Lett. 277, 1
(1999).
26. Lecci A., Giuliani S., Tramontana M., Criscuoli
M., Maggi C.A.: J. Urol. 163, 638 (2000).
27. Sellers D.J., McKay N.: Curr. Opin. Urol. 17,
223 (2007).
28. DeRidder D., Baert L.: BJU Int. 86, 172 (2000).
29. Avelino A., Cruz F.: Naunyn Schmiedebergs
Arch. Pharmacol. 373, 287 (2006).
30. Araki I., Du S., Kobayashi H., Sawada N.,
Mochizuki T., Zakoji H., Takeda M.: Int. J.
Urol. 15, 681 (2008).
31. Schroder A., Newgreen D., Andersson K.E.: J.
Urol. 172, 1166 (2004).
32. Takagi-Matsumoto H., Ng B., Tsukimi Y.,
Tajimi M.: J. Pharm. Sci. 95, 458 (2004).
33. Badawi J.K., Li H., Langbein S., Kwon S.T.,
Kamp S., Bross S.: Eur. J. Clin. Pharmacol. 62,
347 (2006).
34. Naglie G., Radomski S.B., Brymer C.,
Mathiasen K., OíRourke K., Tomlinson G.: J.
Urol. 167, 586 (2002).
35. Yanai I., Hashitani H., Kubota Y., Sasaki S.,
Kohri K., Suzuki H.: BJU Int. 97, 182 (2006).
36. Srikrishna S., Robinson D., Cardozo L., Vella
M.: Postgrad. Med. J. 83, 481 (2007).
37. Pandita R.K., Ronn L.C., Jensen B.F.,
Andersson K.E.: J. Urol. 176, 1220 (2006).
38. Chapple C.R., Patroneva A., Raines S.R.: Eur.
Urol. 49, 879 (2006).
39. Streng T., Christoph T., Andersson K.E.: J.
Urol. 172 (5 Pt 1), 2054 (2004).
40. Kellenberger S., Schild L.: Physiol. Rev. 82,
735 (2002).
41. Araki I.S., Du S., Kamiyama M.: Urology 64,
1255 (2004).
42. Wemmie J.A., Price M.P., Welsh M.J.: Trends
Neurosci. 29, 578 (2006).
43. Karsenty G., Denys P., Amarenco G., De Seze
M., Game X., Haab F., Kerdraon J. et al.: Eur.
Urol. 53, 275 (2008).
44. Dmochowski R.R.: BJU Int. 99 (Suppl. 3), 13
(2007).
45. Milsom I., Abrams P., Cardozo L., Roberts
R.G., Thuroff J., Wein A.J.: BJU Int. 87, 760
(2001).
46. Stewart W.F., Van Rooyen J.B., Cundiff G.W.,
Abrams P., Herzog A.R., Corey R., Hunt T.L.,
Wein AJ.: Word J. Urol. 20, 327 (2003).
47. Corcos J., Schick E.: Can. J. Urol. 11, 2278
(2004).
48. Castro D., Espuna M., Prieto M., Badia X.:
Arch. Esp. Urol. 58, 131 (2005).
49. Temml C., Heidler S., Ponholzer A.,
Madersbacher S.: Eur. Urol. 48, 622 (2005).
50. Irwin D.E., Milsom I., Hunskaar S., Reilly K.,
Kopp Z., Herschorn S., Coyne K., Kelleher C.,
Hampel C., Artibani W., Abrams P.: Eur. Urol.
50, 1306 (2006).
51. Tikkinen K.A., Tammela T.L., Rissanen A.M.,
Valpas A., Huhtala H., Auvinen A.: PLoS ONE
2, e195 (2007). 
52. Herschorn S., Gajewski J., Schulz J., Corcos J.:
BJU Int. 101, 52 (2007).
53. Lawrence J.M., Lukacz E.S., Nager C.W., Hsu
J.W., Luber K.M.: Obstet. Gynecol. 111, 678
(2008).
Received: 11. 10. 2010
